Literature DB >> 12397050

Iron status and hemoglobin level in chronic renal insufficiency.

Chi-Yuan Hsu1, Charles E McCulloch, Gary C Curhan.   

Abstract

Much has been written on the important contribution of iron deficiency toward anemia and epoetin resistance among end-stage renal disease (ESRD) patients, but there are few studies of iron status among chronic renal insufficiency (CRI) subjects not yet requiring dialysis. The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) Practice Guidelines recommend maintaining ferritin > or =100 ng/ml and transferrin saturation (TSAT) > or =20% to ensure adequate iron supply for erythropoiesis among patients with chronic kidney disease, whether or not they are dialysis-dependent. Analysis of the nationally representative data from the Third National Health and Nutrition Examination Survey (NHANES III 1988-1994) revealed that only a minority of anemic CRI subjects in the United States met these K/DOQI targets. For example, in the range of creatinine clearance (CrCl) 30 to 50 ml/min, less than one third of men with hemoglobin <12 g/dl and women with hemoglobin <11 g/dl had ferritin > or =100 ng/ml and TSAT > or =20%. In addition, TSAT levels above 20% were independently associated with higher hemoglobin levels. Such data raise the question whether the K/DOQI targets should be reevaluated. It is concluded that ferritin and TSAT targets derived from ESRD studies may not be applicable to subjects with CRI. Further studies are needed to guide optimization of iron status and hemoglobin level in the much larger CRI population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12397050     DOI: 10.1097/01.asn.0000034200.82278.dc

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  27 in total

1.  Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.

Authors:  Ali C M Johnson; Kirsten Becker; Richard A Zager
Journal:  Am J Physiol Renal Physiol       Date:  2010-05-26

Review 2.  Intravenous iron in heart failure: beyond targeting anemia.

Authors:  Donald S Silverberg; Adrian Iaina; Doron Schwartz; Dov Wexler
Journal:  Curr Heart Fail Rep       Date:  2011-03

3.  A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.

Authors:  Daniel Moj; Hugo Maas; André Schaeftlein; Nina Hanke; José David Gómez-Mantilla; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

4.  Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

Authors:  Robert Provenzano; Brigitte Schiller; Madhumathi Rao; Daniel Coyne; Louis Brenner; Brian J G Pereira
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-28       Impact factor: 8.237

5.  Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?

Authors:  Simona Stancu; Liliana Bârsan; Ana Stanciu; Gabriel Mircescu
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-17       Impact factor: 8.237

6.  Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004.

Authors:  Steven Fishbane; Simcha Pollack; Harold I Feldman; Marshall M Joffe
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 8.237

7.  Selected physiologic variables are weakly to moderately associated with 29 biomarkers of diet and nutrition, NHANES 2003-2006.

Authors:  Bridgette M H Haynes; Christine M Pfeiffer; Maya R Sternberg; Rosemary L Schleicher
Journal:  J Nutr       Date:  2013-04-17       Impact factor: 4.798

8.  Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis.

Authors:  Vicente Escudero-Vilaplana; Concepción Martínez-Nieto; Juan Manuel López-Gómez; Almudena Vega-Martínez; José María Bellón-Cano; María Sanjurjo-Sáez
Journal:  Int J Clin Pharm       Date:  2013-04-18

9.  Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease.

Authors:  Roberto Minutolo; Paolo Chiodini; Bruno Cianciaruso; Andrea Pota; Vincenzo Bellizzi; Deborah Avino; Sara Mascia; Simona Laurino; Valerio Bertino; Giuseppe Conte; Luca De Nicola
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

10.  Association between iron deficiency and A1C Levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999-2006.

Authors:  Catherine Kim; Kai McKeever Bullard; William H Herman; Gloria L Beckles
Journal:  Diabetes Care       Date:  2010-01-12       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.